Literature DB >> 33539378

Gene expression profiles of liver cancer cell lines reveal two hepatocyte-like and fibroblast-like clusters.

Keita Fukuyama1, Masataka Asagiri2,3, Masahiro Sugimoto4, Hiraki Tsushima5, Satoru Seo1, Kojiro Taura1, Shinji Uemoto1, Keiko Iwaisako1,3,5.   

Abstract

Cancer cell lines are widely used in basic research to study cancer development, growth, invasion, or metastasis. They are also used for the development and screening of anticancer drugs. However, there are no clear criteria for choosing the most suitable cell lines among the wide variety of cancer cell lines commercially available for research, and the choice is often based on previously published reports. Here, we investigated the characteristics of liver cancer cell lines by analyzing the gene expression data available in the Cancer Cell Line Encyclopedia. Unsupervised clustering analysis of 28 liver cancer cell lines yielded two main clusters. One cluster showed a gene expression pattern similar to that of hepatocytes, and the other showed a pattern similar to that of fibroblasts. Analysis of hepatocellular carcinoma gene expression profiles available in The Cancer Genome Atlas showed that the gene expression patterns in most hepatoma tissues were similar to those in the hepatocyte-like cluster. With respect to liver cancer research, our findings may be useful for selecting an appropriate cell line for a specific study objective. Furthermore, our approach of utilizing a public database for comparing the properties of cell lines could be an attractive cell line selection strategy that can be applied to other fields of research.

Entities:  

Mesh:

Year:  2021        PMID: 33539378      PMCID: PMC7861371          DOI: 10.1371/journal.pone.0245939

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  41 in total

Review 1.  What's wrong with our cancer models?

Authors:  Alexander Kamb
Journal:  Nat Rev Drug Discov       Date:  2005-02       Impact factor: 84.694

Review 2.  Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy.

Authors:  Renumathy Dhanasekaran; Jean-Charles Nault; Lewis R Roberts; Jessica Zucman-Rossi
Journal:  Gastroenterology       Date:  2018-11-04       Impact factor: 22.682

3.  Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity.

Authors:  Scott M Wilhelm; Jacques Dumas; Lila Adnane; Mark Lynch; Christopher A Carter; Gunnar Schütz; Karl-Heinz Thierauch; Dieter Zopf
Journal:  Int J Cancer       Date:  2011-04-22       Impact factor: 7.396

4.  Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials.

Authors:  Thomas G Roberts; Bernardo H Goulart; Lee Squitieri; Sarah C Stallings; Elkan F Halpern; Bruce A Chabner; G Scott Gazelle; Stan N Finkelstein; Jeffrey W Clark
Journal:  JAMA       Date:  2004-11-03       Impact factor: 56.272

5.  Characteristics of cell lines established from human colorectal carcinoma.

Authors:  J G Park; H K Oie; P H Sugarbaker; J G Henslee; T R Chen; B E Johnson; A Gazdar
Journal:  Cancer Res       Date:  1987-12-15       Impact factor: 12.701

6.  Growth of human hepatoma cells lines with differentiated functions in chemically defined medium.

Authors:  H Nakabayashi; K Taketa; K Miyano; T Yamane; J Sato
Journal:  Cancer Res       Date:  1982-09       Impact factor: 12.701

7.  Clinical approval success rates for investigational cancer drugs.

Authors:  J A DiMasi; J M Reichert; L Feldman; A Malins
Journal:  Clin Pharmacol Ther       Date:  2013-06-05       Impact factor: 6.875

Review 8.  Role of epithelial to mesenchymal transition in hepatocellular carcinoma.

Authors:  Gianluigi Giannelli; Petra Koudelkova; Francesco Dituri; Wolfgang Mikulits
Journal:  J Hepatol       Date:  2016-05-17       Impact factor: 25.083

9.  The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Authors:  Jordi Barretina; Giordano Caponigro; Nicolas Stransky; Kavitha Venkatesan; Adam A Margolin; Sungjoon Kim; Christopher J Wilson; Joseph Lehár; Gregory V Kryukov; Dmitriy Sonkin; Anupama Reddy; Manway Liu; Lauren Murray; Michael F Berger; John E Monahan; Paula Morais; Jodi Meltzer; Adam Korejwa; Judit Jané-Valbuena; Felipa A Mapa; Joseph Thibault; Eva Bric-Furlong; Pichai Raman; Aaron Shipway; Ingo H Engels; Jill Cheng; Guoying K Yu; Jianjun Yu; Peter Aspesi; Melanie de Silva; Kalpana Jagtap; Michael D Jones; Li Wang; Charles Hatton; Emanuele Palescandolo; Supriya Gupta; Scott Mahan; Carrie Sougnez; Robert C Onofrio; Ted Liefeld; Laura MacConaill; Wendy Winckler; Michael Reich; Nanxin Li; Jill P Mesirov; Stacey B Gabriel; Gad Getz; Kristin Ardlie; Vivien Chan; Vic E Myer; Barbara L Weber; Jeff Porter; Markus Warmuth; Peter Finan; Jennifer L Harris; Matthew Meyerson; Todd R Golub; Michael P Morrissey; William R Sellers; Robert Schlegel; Levi A Garraway
Journal:  Nature       Date:  2012-03-28       Impact factor: 49.962

Review 10.  Systemic treatment for hepatocellular carcinoma: Still unmet expectations.

Authors:  Dimitrios N Samonakis; Elias A Kouroumalis
Journal:  World J Hepatol       Date:  2017-01-18
View more
  2 in total

1.  Expression and Functionality of Connexin-Based Channels in Human Liver Cancer Cell Lines.

Authors:  Kaat Leroy; Cícero Júlio Silva Costa; Alanah Pieters; Bruna Dos Santos Rodrigues; Raf Van Campenhout; Axelle Cooreman; Andrés Tabernilla; Bruno Cogliati; Mathieu Vinken
Journal:  Int J Mol Sci       Date:  2021-11-10       Impact factor: 5.923

2.  VEGF-mediated tumour growth and EMT in 2D and 3D cell culture models of hepatocellular carcinoma.

Authors:  Preety Rawal; Dinesh Mani Tripathi; Vikrant Nain; Savneet Kaur
Journal:  Oncol Lett       Date:  2022-07-15       Impact factor: 3.111

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.